News | Nuclear Imaging | June 08, 2016

Nuclear Medicine Market Shows Slow Growth Since 2014

Medraysintell report says growth has been affected the molybdenum-99 shortage, exchanges rates

nuclear medicine, global market, radiopharmaceuticals, MEDraysintell, SNMMI 2016

June 8, 2016 — MEDraysintell estimates that the global market for nuclear medicine (radiopharmaceuticals) reached $4.3 billion in 2015, growing just over 2 percent a year between 2013 and 2015. This slow growth is primarily driven by lower revenues from technetium-99m-related products and an unfavorable impact from U.S. dollar exchange rates versus major currencies.

This slow progression is compensated by a robust increase of radiotherapeutics, which have grown by about 60 percent a year from 2013 to 2015, mostly driven by one product, Xofigo from Bayer. Without this exchange rate influence, MEDraysintell estimates that the nuclear medicine market would have reached over $4.7 billion in 2015, thereby exhibiting an annual growth of more than 7 percent for the period 2013-2015.

While it has been stable the last year, the global nuclear medicine market is expected to climb to $25 billion by 2030. Several factors indicate an increasing demand for nuclear medicine procedures, including a wider use of nuclear medicine around the world (other applications besides oncology and cardiology) and the introduction of new radiopharmaceuticals. The molybdenum-99 shortage issue, which will be solved within the next two years with domestic U.S. reactors coming online, will also influence additional growth. Yet, the most important factor that will shape the future growth of the nuclear medicine market is the launch of new-generation therapeutic radiopharmaceuticals.

All these topics are covered in the new Nuclear Medicine World Market Report & Directory, Edition 2016 to be published shortly after the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2016 annual meeting, June 11-15 in San Diego. The 990–page report and directory describes and analyzes over 360 radiopharmaceuticals and radionuclides and more than 160 companies and institutions active in nuclear medicine.

For more information: www.medraysintell.org

Related Content

iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
ASTRO Applauds Introduction of PIMA Patient Protection Bill
News | Radiology Business | April 15, 2019
The American Society for Radiation Oncology (ASTRO) hailed the introduction of federal legislation that would...
Videos | Radiology Business | March 22, 2019
American Society of Radiologic Technologists (ASRT) President Melissa Jackowski, Ed.D., R.T.(R)(M), FASRT, explains e
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
ASRT Elects Four New Officers for 2019
News | Radiology Business | March 22, 2019
March 22, 2019 — Members of the Americ...
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...